- Home
- CSBR vs ISSC Comparison
CSBR vs ISSC Comparison
Compare CSBR & ISSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- ISSC
- Stock Information
- Founded
- CSBR 1985
- ISSC 1988
- Country
- CSBR United States
- ISSC United States
- Employees
- CSBR N/A
- ISSC N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- ISSC EDP Services
- Sector
- CSBR Health Care
- ISSC Technology
- Exchange
- CSBR Nasdaq
- ISSC Nasdaq
- Market Cap
- CSBR 135.5M
- ISSC N/A
- IPO Year
- CSBR 1986
- ISSC 2000
- Fundamental
- Price
- CSBR $8.61
- ISSC $6.42
- Analyst Decision
- CSBR Strong Buy
- ISSC
- Analyst Count
- CSBR 1
- ISSC 0
- Target Price
- CSBR $12.00
- ISSC N/A
- AVG Volume (30 Days)
- CSBR 44.2K
- ISSC 91.6K
- Earning Date
- CSBR 03-11-2025
- ISSC 05-12-2025
- Dividend Yield
- CSBR N/A
- ISSC N/A
- EPS Growth
- CSBR N/A
- ISSC 3.71
- EPS
- CSBR 0.46
- ISSC 0.38
- Revenue
- CSBR $58,591,000.00
- ISSC $53,858,686.00
- Revenue This Year
- CSBR $14.19
- ISSC $31.35
- Revenue Next Year
- CSBR $10.11
- ISSC $16.39
- P/E Ratio
- CSBR $18.82
- ISSC $16.57
- Revenue Growth
- CSBR 19.03
- ISSC 43.24
- 52 Week Low
- CSBR $3.60
- ISSC $4.91
- 52 Week High
- CSBR $11.99
- ISSC $12.17
- Technical
- Relative Strength Index (RSI)
- CSBR 39.31
- ISSC 35.57
- Support Level
- CSBR $9.21
- ISSC $6.65
- Resistance Level
- CSBR $9.97
- ISSC $6.81
- Average True Range (ATR)
- CSBR 0.65
- ISSC 0.25
- MACD
- CSBR -0.10
- ISSC 0.07
- Stochastic Oscillator
- CSBR 15.74
- ISSC 27.72
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.